GlassScriptPhysician profile
Manu M Mysore
NPI 1427410109
$3,955.81
in general payments reported to CMS, 2019-2025
9 companies · $1,722 in 2025
The $1,722 reported for 2025 was more than what 97% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $92.82 · 2022: $49.53 · 2023: $41.65 · 2024: $2,050 · 2025: $1,722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,411 · Food and Beverage: $1,402.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,411.22 |
| Food and Beverage | $1,402.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,863.19 | 2024-2025 | Evoque, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Pascal |
| Abbott Laboratories | $1,639.44 | 2025 | Triclip |
| Abiomed | $147.33 | 2023-2024 | Impella |
| Amgen INC. | $125.00 | 2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $55.20 | 2021 | |
| W. L. Gore & Associates, INC. | $49.53 | 2022 | |
| Pfizer INC. | $35.63 | 2021-2023 | |
| Getinge USA Sales, LLC | $21.30 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $19.19 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manu Mysore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.